Mirabaud & Cie’s Moderna MRNA Stock Holding History

Mirabaud & Cie’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.91M	Sell	9,934 -7,220	-42%	-$778K	0.74%	26
2026 Q2	$1.2M	Sell	17,154 -1,212	-7%	-$62.7K	0.48%	29
2026 Q1	$933K	Sell	18,366 -32,060	-64%	-$1.5M	0.38%	32
2025 Q4	$1.49M	Sell	50,426 -120	-0.2%	-$3.26K	0.48%	27
2025 Q3	$1.31M	Sell	50,546 -9,486	-16%	-$265K	0.41%	36
2025 Q2	$1.66M	Sell	60,032 -1,510	-2%	-$39.8K	0.53%	36
2025 Q1	$1.74M	Buy	61,542 +3,520	+6%	+$125K	0.6%	31
2024 Q4	$2.41M	Buy	58,022 +1,694	+3%	+$81K	0.77%	27
2024 Q3	$3.76M	Buy	56,328 +350	+0.6%	+$32.1K	1.09%	22
2024 Q2	$6.65M	Sell	55,978 -295	-0.5%	-$37.3K	2.25%	13
2024 Q1	$6M	Sell	56,273 -10,410	-16%	-$1.05M	2.11%	16
2023 Q4	$6.63M	Buy	+66,683	New	+$5.61M	2.21%	18

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return

Beau Ventures Pittsford, New York $1.06B AUM 83.06% 1-Year Est. Return

Mirabaud & Cie's MRNA Position: Q3 2026 in Review

Mirabaud & Cie reduced its Moderna (MRNA) stake by 42% in Q3 2026, selling an estimated $778K and leaving 9,934 shares worth $1.91M. The position accounts for 0.74% of the portfolio, ranked #26.

Mirabaud & Cie first reported a position in MRNA in Q4 2023 and has held it in 12 quarters since. The position peaked at $6.65M in Q2 2024. 633 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

Mirabaud & Cie held 9,934 shares of Moderna worth $1.91M as of Q3 2026.
Mirabaud & Cie sold 7,220 Moderna shares in Q3 2026, an estimated $778K.
Moderna made up 0.74% of Mirabaud & Cie's portfolio in Q3 2026, its #26 holding.
Mirabaud & Cie first reported a position in Moderna in Q4 2023 and has held it in 12 quarters since.
Mirabaud & Cie's Moderna position peaked at $6.65M in Q2 2024.
633 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Mirabaud & Cie's 13F filing for Q3 2026, filed 27 Oct 2026.